These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 21055188)

  • 1. [Mucosal biopsy diagnosis of Barrett's esophageal: an update].
    Wang L; Wang LP
    Zhonghua Bing Li Xue Za Zhi; 2010 Jul; 39(7):497-500. PubMed ID: 21055188
    [No Abstract]   [Full Text] [Related]  

  • 2. [Biopsy methods and pathology of Barrett's esophagus].
    Takubo K; Honma N; Sawabe M; Arai T; Tanaka Y; Kino K; Iwakiri K
    Nihon Rinsho; 2005 Aug; 63(8):1429-33. PubMed ID: 16101234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDX2 and villin are useful markers of intestinal metaplasia in the diagnosis of Barrett esophagus.
    Shi XY; Bhagwandeen B; Leong AS
    Am J Clin Pathol; 2008 Apr; 129(4):571-7. PubMed ID: 18343784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total endoscopic eradication of Barrett's esophagus: study methodology, candidate selection, and clinical outcomes.
    Shaheen NJ; Spechler SJ
    Endoscopy; 2008 Dec; 40(12):994-9. PubMed ID: 19065482
    [No Abstract]   [Full Text] [Related]  

  • 5. CDX2 and LI-cadherin expression in esophageal mucosa: use of both markers can facilitate the histologic diagnosis of Barrett's esophagus and carcinoma.
    Weimann A; Zimmermann M; Gross M; Slevogt H; Rieger A; Morawietz L
    Int J Surg Pathol; 2010 Oct; 18(5):330-7. PubMed ID: 20444732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus.
    Villanacci V; Rossi E; Zambelli C; Galletti A; Cestari R; Missale G; Casa DD; Bassotti G
    Dig Liver Dis; 2007 Apr; 39(4):305-11. PubMed ID: 17307036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokeratin and CDX-2 expression in Barrett's esophagus.
    van Baal JW; Bozikas A; Pronk R; Ten Kate FJ; Milano F; Rygiel AM; Rosmolen WD; Peppelenbosch MP; Bergman JJ; Krishnadath KK
    Scand J Gastroenterol; 2008; 43(2):132-40. PubMed ID: 18224560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokeratin and DAS-1 immunostaining reveal similarities among cardiac mucosa, CIM, and Barrett's esophagus.
    DeMeester SR; Wickramasinghe KS; Lord RV; Friedman A; Balaji NS; Chandrasoma PT; Hagen JA; Peters JH; DeMeester TR
    Am J Gastroenterol; 2002 Oct; 97(10):2514-23. PubMed ID: 12385432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of CDX2 and MUC2 in Barrett's mucosa.
    Steininger H; Pfofe DA; Müller H; Haag-Sunjic G; Fratianu V
    Pathol Res Pract; 2005; 201(8-9):573-7. PubMed ID: 16259110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting surveillance in Barrett's esophagus.
    Hillman L
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1311-2. PubMed ID: 18853989
    [No Abstract]   [Full Text] [Related]  

  • 11. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
    Lord RV; Brabender J; Wickramasinghe K; DeMeester SR; Holscher A; Schneider PM; Danenberg PV; DeMeester TR
    Surgery; 2005 Nov; 138(5):924-31. PubMed ID: 16291394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maspin differential expression patterns as a potential marker for targeted screening of esophageal adenocarcinoma/gastroesophageal junction adenocarcinoma.
    Dzinic SH; Mahdi Z; Bernardo MM; Vranic S; Beydoun H; Nahra N; Alijagic A; Harajli D; Pang A; Saliganan DM; Rahman AM; Skenderi F; Hasanbegovic B; Dyson G; Beydoun R; Sheng S
    PLoS One; 2019; 14(4):e0215089. PubMed ID: 31002675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expression of 8-hydroxydeoxyguanosine in oesophageal tissues and tumours.
    Räsänen JV; Sihvo EI; Ahotupa MO; Färkkilä MA; Salo JA
    Eur J Surg Oncol; 2007 Dec; 33(10):1164-8. PubMed ID: 17467227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered expression of CD44 and DKK1 in the progression of Barrett's esophagus to esophageal adenocarcinoma.
    Darlavoix T; Seelentag W; Yan P; Bachmann A; Bosman FT
    Virchows Arch; 2009 Jun; 454(6):629-37. PubMed ID: 19396460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Limited surgical resection versus local endoscopic therapy of early cancers of the esophagogastric junction].
    von Rahden BH; Feith M; Stein HJ
    Zentralbl Chir; 2006 Apr; 131(2):97-104. PubMed ID: 16612774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Barrett's esophagus].
    Kawano T; Iwai T
    Nihon Rinsho; 2000 Sep; 58(9):1903-7. PubMed ID: 11004824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zoning of mucosal phenotype, dysplasia, and telomerase activity measured by telomerase repeat assay protocol in Barrett's esophagus.
    Going JJ; Fletcher-Monaghan AJ; Neilson L; Wisman BA; van der Zee A; Stuart RC; Keith WN
    Neoplasia; 2004; 6(1):85-92. PubMed ID: 15068673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Esophagogastric junctional adenocarcinoma originating from endoscopically unrecognizable Barrett's epithelium.
    Nagai K; Tsujii Y; Matsui T; Yoshii S; Fujinaga T; Maekawa A; Inoue T; Hayashi Y; Shinzaki S; Iijima H; Tsujii M; Morii E; Takehara T
    Dis Esophagus; 2016 Nov; 29(8):1164-1166. PubMed ID: 26228204
    [No Abstract]   [Full Text] [Related]  

  • 19. Cardiac mucosa indicates risk for Barrett esophagus.
    Lenglinger J; Ringhofer C; Riegler FM
    World J Gastroenterol; 2006 Aug; 12(32):5259. PubMed ID: 16937547
    [No Abstract]   [Full Text] [Related]  

  • 20. Cdx1 and c-Myc foster the initiation of transdifferentiation of the normal esophageal squamous epithelium toward Barrett's esophagus.
    Stairs DB; Nakagawa H; Klein-Szanto A; Mitchell SD; Silberg DG; Tobias JW; Lynch JP; Rustgi AK
    PLoS One; 2008; 3(10):e3534. PubMed ID: 18953412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.